Hadassah

Stem Cell Trial at Hadassah Reveals Significant Positive Results for ALS Patients

Thursday, Jan 8 2015

Israel's BrainStorm Cell Therapeutics has reported that final results of its clinical trial conducted at the Hadassah Medical Organization using adult stem cells to treat amyotrophic lateral sclerosis (ALS) indicate that most patients experienced a slowing of their disease's progression.

Principal Investigator Prof. Dimitrios Karussis, Senior Neurologist at the Hadassah Medical Center and Director of its Multiple Sclerosis Center, presented the interim results of this Phase IIa study at the 2014 Joint Congress of European Neurology in Istanbul. Prof. Karussis and Hadassah’s team, including Prof. Tamir Ben-Hur, Chair of Neurology, started work on clinical application of stem cell treatment in 2007 and published their results in 2010. “We then partnered with BrainStorm,” Prof. Karussis relates, “which combined the cells with hormones, including growth factors, to improve the performance outcomes.” It was Prof. Ben-Hur’s pioneering research, however, that laid the scientific foundation for the current use of stem cells to inhibit brain inflammation and protect the brain in treating multiple sclerosis. These principles of using stem cells for therapy were then expanded for additional conditions, such as ALS.

A single dose of the stem cell treatment called NurOwn was administered in a mid-stage phase IIa trial in 14 patients with ALS, also known as Lou Gehrig's Disease. “Nearly all subjects in this study experienced clinical benefit from treatment with NurOwn," the company spokesman said. “Of the 12 patients with three or more months of follow-up, 92 percent experienced an improvement in regard to the progression of their disease.” Furthermore, BrainStorm reports, NurOwn had a strong effect on the rate of decline in lung function.

"We observed individuals with prolonged stabilization and even improvements in function, and this was achieved with just a single dose of NurOwn," commented BrainStorm Chief Executive Tony Fiorino.

BrainStorm, which is also conducting clinical trials at three sites in the United States, plans to initiate a study in the next few months to see if the results can be amplified with repeated doses.

Comments

From: leanne on April 12, 2016
Hi Im 35 yrs old from Australia and was diagnosed with MND (limb onset) in July 2015. I am very interested in participating in your trial. Can I trouble you to provide me with further information? Kind Regards Leanne
From: Susana on January 16, 2016
My husband has been diagnosed with MND ( Bulbar Onset) We are very interested in taking part in your trials and receiving any treatment or advice from your department. Thank you Susana
From: Robin on November 29, 2015
Are you doing any clinical trials in the States now? I know someone who would really benefit from participating, diagnosed with ALS last year. If not, are there active trials going on in Israel?
From: Jing on November 28, 2015
My sister was diagnosed ALS in May this year. She is at the early stage but it is progressing worse rapidly. Is there a possibility for her to participate in your NurOwn clinical trial? Thanks.
From: FAbio on September 9, 2015
Me diagnosticaron ELA en mayo 2013, comenzo en la pierna izq, al dia de hoy hace 2 meses q estoy en sillas de ruedas, sin ningun otro problema, necesito contactarme para realizar el trat. con NurOwn. Gracias
From: James on September 1, 2015
I am first stage MS since 2009 then 58, now 69 . Walking especially in hot weather, stairs, balance, getting up from chairs. Only two attacks in total, take copaxone 3 per week. Is stem cells a possibility for me, is it safe, how much , etc. Thanks
From: Stanley on August 30, 2015
I have been diagnosed as Motor Neuron disorder/ALS and would consider entering a Stem Cell clinical trial. Please let me know what is available in Israel and also any United States trials.
From: Nancy on August 2, 2015
Please may I participate in the stem cell study? I will travel anywhere to be a part of it.
From: Katja on July 21, 2015
PLEASE give me more information about stemcell operations. I am 43 years old (teacher of speechhandicapped children), beginning ALS, mother of two girls (8, 10 years). Is there an oportunity to get stem cells at your house (or in Germany) and what are the costs. Please help me! Thank you!!!
From: Ruthie on January 21, 2015
when my husband was (finally and properly) diagnosed with ALS in 1996, Hadassah was not researching this disease. Bravo to Hadassah for continuing to research this and other neurological diseases at this time!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More